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Ethnopharmacological relevance: Atopic dermatitis is a common chronic inﬂammatory skin condition
that is on the rise and adversely affects quality of life of the affected individual. Dry skin and pruritus,
major characteristics of this disease, are associated with the dysfunction of the skin barrier. Though mild
cases of the disease can be controlled with antihistamines and topical corticosteroids, moderate-to-se-
vere cases often require treatment with immunomodulatory drugs, which have many side effects. It is
now more common to use complementary and alternative medicines in the treatment of atopic der-
matitis. In traditional Iranian medicine, the use of whey with the aqueous extract of ﬁeld dodder (Cuscuta
campestris Yunck.) seeds in severe and refractory cases of atopic dermatitis is common and has no side
effects.
The aim of this study was to assess the efﬁcacy and safety of whey associated with dodder seed
extract in the treatment of moderate-to-severe atopic dermatitis in adults.
Materials and methods: The study was a randomized, double-blind placebo control trial that was con-
ducted on 52 patients with moderate-to-severe atopic dermatitis for 30 days. In this study patients
received freeze dried whey powder with spray dried water extract of ﬁeld dodder or the placebo for 15
days. At baseline (week zero), after the end of the 15 day treatment period (week three) and 15 days after
stopping the drug or placebo (follow-up/week ﬁve), patients were evaluated in terms of skin moisture,
elasticity, pigmentation, surface pH and sebum content on the forearm with Multi Skin Test Centers
MC1000 (Courage & Khazaka, Germany) and the degree of pruritus and sleep disturbance in patients
were also recorded.
Results: 42 patients completed 30 days of treatment with the medicine and the follow-up period. At the
end of the follow-up period a signiﬁcant increase in skin moisture and elasticity in the group receiving
whey with dodder was observed compared with the placebo group (po0.001). There was a signiﬁcant
difference between the two groups regarding the pruritus after 15 days of receiving treatment or the
placebo (po0.05), and at the end of the 30-day study period the difference was clearly signiﬁcant
(po0.001). Sleep disturbance showed signiﬁcant changes at the end of follow-up period (po0.05).
There was no signiﬁcant difference between the two groups concerning changes in skin pigmentation,
however, a signiﬁcant decrease was observed in the group receiving whey associated with dodder seed
extract over time (po0.001). There were no signiﬁcant alterations in skin surface pH and the amount of
sebum between the two groups. Temporary side effects were reported including anorexia and mild
gastrointestinal problems in drug use.
It is noteworthy that in this study despite the fact that patients received whey with dodder for just 15
days, moisture and elasticity of the skin continued to increase in the second half of the study (follow-up
period). This shows that the effect of whey with dodder is not transient and this drug really helped skin
barrier reconstruction and accelerated the healing process of skin. This positively inﬂuenced the skin
parameters and consequently the improvement of pruritus and sleep disturbance.rved.
ines Research Center, Kerman University of Medical Sciences, Haft-bagh Ave., Kerman, Iran. Fax: þ98 3432532452.
ehrabani).
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alternative for the treatment of moderate-to-severe atopic dermatitis.
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Atopic dermatitis (AD) is a common chronic inﬂammatory and
pruritic skin disease, often associated with a positive family his-
tory of allergic diseases, such as allergic rhinitis and asthma (Leung
et al., 2004). The disease has a devastating effect on quality of life.
The eczematous skin lesions with severe pruritus lead to disrupted
sleep and decreased daily performance and social activities of
patients in addition to signiﬁcant ﬁnancial expenses for both the
families of patients and society, as well (Fivenson et al., 2002). AD
affects 15–30% of children and 2–10% of adults (Bieber, 2008).
Prevalence in developing countries is more than 10% in the general
population and is increasing day by day, while in developed
countries prevalence has reached a level plateau of approximately
20% (Kim, 2013). Atopic dermatitis occurs in those who are ge-
netically predisposed. Mutations in the ﬁlaggrin gene, which is a
key protein in formation of the skin barrier and skin moistening,
lead to skin barrier dysfunction. Skin barrier damage increases
transepidermal water loss and permits the entry of environmental
antigens and allergens from the epidermis leading to in-
ﬂammatory responses (Howell et al., 2009). Topical corticoster-
oids, emollients and oral antihistamines are used in mild disease
without too many side effects, but many patients with moderate-
to-severe atopic dermatitis require systemic immunomodulating
treatment (e.g., cyclosporine, azathioprine, systemic corticoster-
oids and methotrexate) with unfavourable side effects (Hong et al.,
2011; Roekevisch et al., 2014).
Since effective treatments for the disease are limited, there is a
tendency toward ﬁnding better and safer therapies. Among them,
the use of complementary and alternative medicines (CAM) is
growing in the treatment of inﬂammatory skin diseases, particu-
larly AD (Boneberger et al., 2010). Traditional Iranian Medicine
(TIM), with a long history of several thousand years, offers effec-
tive treatments in this ﬁeld with diet and lifestyle modiﬁcation
and drugs of a plant or animalistic origin. TIM recommends the
use of topical emollients and wet compression in mild AD. In TIM,
one of the most common treatments for chronic and severe cases
of atopic dermatitis is the use of whey with the aqueous extract of
ﬁeld dodder seeds (Avicenna, 2005; Rhazes, 1990).
Whey is a protein complex derived from milk and considered a
functional food. Whey has several properties as an antitumor,
antihypertensive, hypolipidaemic, antiviral, antibacterial, anti-
ageing and chelating agent. Whey possesses potent antioxidant
activity as a result of intracellular conversion of the amino acid
cysteine into glutathione, which is an intracellular potent anti-
oxidant (Marshall, 2004). Whey's healing properties have been
recognized since the 5th century BC and whey cure has been re-
commended by Hippocrates, Galen, Avicenna, Rhazes, and other
famous names from the history of medicine. Whey has been used
for medicinal purposes, including gout, sepsis, wound healing, as
well as liver and stomach diseases (Avicenna, 2005; Rhazes, 1990;
Smithers, 2008; Vasey, 2006).
Field dodder, with the scientiﬁc name of Cuscuta campestris
Yuncker (Family Convolvulaceae) and traditional name of afti-
moun, is a parasitic plant without leaves, yellowish green stems
climbing the winder and sweet-scented white ﬂowers (Fernald,
1970). Different Cuscuta species are widely used as medicinal
plants in traditional medicine in the treatment of epilepsy,psychosis, paralysis, cancer, skin diseases, etc. (Aghili Khorasani,
2011a). C. campestris Yunck. is the most widespread species in the
genus Cuscuta in the world (Holm et al., 1997). This plant has
analgesic, hypothermic, anti-inﬂammatory, anti-proliferative ef-
fects and CNS depression activity (Agha et al., 1996). Cuscuta seed
extract contains a variety of ﬂavonoids, polysaccharides, alkaloids
and other chemicals. Among the ﬂavonoids, quercetin is a ther-
apeutic compound for inﬂammatory and autoimmune diseases
with immunomodulating effects (Lee et al., 2011).
The aim of this study was to assess the efﬁcacy and safety of
whey associated with dodder seed extract (WaDSE) in the treat-
ment of moderate-to-severe atopic dermatitis in adults that was
conducted as a randomized, double-blind, placebo-controlled trial.2. Materials and methods
2.1. Patients
52 patients with moderate-to-severe atopic dermatitis referred
to the Dermatology Clinic of Afzalipour Hospital, Kerman Uni-
versity of Medical Sciences, Iran, have entered into the trial after
the conﬁrmation of diagnostic criteria for atopic dermatitis (Ha-
niﬁn and Rajka, 1980). Inclusion criteria were as follows: Haniﬁn and Rajka criteria approved for atopic dermatitis.
 Moderate-to-severe atopic dermatitis (SCORADZ25).
 Aged 18 and older.
 Poor response to conventional treatment for atopic dermatitis
(topical steroids and antihistamines).
 AD consistently symptomatic for at least six months.
 Lack of exudates or infection.
 Lack of pregnancy and lactation.
 The absence of concomitant systemic disease (except asthma
and allergic rhinitis).
Patients with abnormalities in blood cell count, liver enzymes
and renal function tests, secondary bacterial infections, who were
receiving systemic corticosteroids and other immunosuppressant
drugs and phototherapy during the study or who demonstrated
drug intolerance symptoms were excluded.
Prior to intervention, informed written consent was obtained
from all patients and patients in both groups were asked to con-
tinue previously received topical steroids with the same strength
and frequency. This study was approved by the Medical Research
Ethics Committee, Shahid Beheshti University of Medical Sciences.
2.2. Drug and placebo preparation
In traditional medicine, ﬁeld dodder seed is used in the treat-
ment of chronic atopic dermatitis as a decoction associated with
whey. In this study, dosage form change was necessary for uni-
formity and ease of use. Thus, a powder form of whey was pre-
pared, and as the dodder seed decoction has a bitter taste, dried
aqueous extract was prepared and administered in capsule form.
2.2.1. Whey
In traditional medicine, whey is produced using three methods:
M. Mehrbani et al. / Journal of Ethnopharmacology 172 (2015) 325–332 327(1) the use of rennet, (2) the use of vinegar, (3) the use of oxymel
(Aghili Khorasani, 2011b). The second method was used in this
study as it is quick and easy. For this purpose, whole cow milk was
boiled and 18 g of pure vinegar per kilogram of milk was added.
After the curds appeared, they were isolated using ﬁne ﬁlters.
Casein and whey, major milk proteins with different properties,
account for approximately 80% and 20% of milk proteins, respec-
tively (Shah, 2000). The curds consist mainly of casein while whey
remains in the aqueous environment. Unlike casein, whey proteins
are not coagulated in the acidic environment of the stomach and
are quickly absorbed when they reach the intestines (Boirie et al.,
1997). As there are heat-sensitive protein structures in the liquid
whey, the freeze drying technique was used to convert it into a
powder form. In order to standardize, the amount of total protein
was measured by the biuret method (Goyal and Gandhi, 2009) and
found to be equal to 3371% (w/w) dry weight. As the therapeutic
dose of liquid whey in atopic dermatitis is 450 ml per day (Aghili
Khorasani, 2011b), its average dry weight was determined as equal
to 3071.5 g (mean7SD, n¼3). Thus, the daily intake of whey
powder was deﬁned as 30 g. The produced powder was packed
into 15 g vacuum-sealed bags.
2.2.2. Dodder seed extract
C. campestris Yunck. plants (ﬁeld dodder) grown on Alhagi
persarum (camel thorn) were collected from the unutilized lands
around the city of Kerman, Iran (located at latitude 30°15′N and
longitude 57°01′E) in August 2013. The sample was authorized and
kept at the Faculty of Pharmacy herbarium, Kerman University of
Medical Sciences, by Dr. Mitra Mehrabani (Voucher specimen No.
2002). Plant material was separated from camel thorn, cleaned,
dried under shade and pulverized to pass a 40 mesh sieve. Aqu-
eous ﬁeld dodder seed extract was prepared according to tradi-
tional methods (Aghili Khorasani, 2011a). The plant seeds were
poured into boiling water and put on medium heat for 20–
30 minutes to be decocted and were then ﬁltered. The aqueous
extract obtained was dried using the spray drying method. Stan-
dardization was done using the rutin ﬂavonoid (quercetin-3-ruti-
noside) measurement by ultraviolet–visible spectrophotometry,
which was equivalent to 11.571.5% (w/w) (Harborne, 1998). The
spray dried extract was ﬁlled in 500 mg capsules. As the average
daily use of dodder seeds is 12 g (Aghili Khorasani, 2011a), dry
weight of the aqueous extract was measured; the mean value was
20007500 mg (mean7SD, n¼3) and the daily dosage was de-
ﬁned as four 500 mg capsules. For each patient, in order to cover
the 15 day trial period, packages containing 30 packets of 15 g of
whey powder and 60 dried extract 500 mg capsules were
prepared.
2.2.3. Placebo
To prepare a placebo similar to whey in terms of colour, shape,
smell and taste, corn starch, cornmeal and lactose in the ratio
6:1:1 were used. The placebo 500 mg capsules were ﬁlled with
corn starch. Packaging was the same as the original drug. This
placebo does not have a known effect on atopic dermatitis.
The drug and placebo were supplied in the School of Tradi-
tional Medicine, Kerman, Iran and all products were controlled in
the Microbial Control Laboratory of the faculty for possible mi-
crobial contamination before use. In order to ﬁngerprint every
batch produced, the whey powder was measured using the biuret
method for total protein, and in the case of the dried dodder ex-
tract, TLC (thin-layer chromatography) was used (Goyal and
Gandhi, 2009; Harborne, 1998).
Patients were instructed to prepare the medicine by mixing a
15 g packet of powder in 200 ml of warm water and consuming it
with two capsules twice a day 30–60 min. before eating breakfast
and dinner.2.3. Assessment
Patients were randomized into two treatment and placebo
groups and received WaDSE or a placebo for 15 days. Five variables
were analysed, including skin moisture, elasticity, pigmentation,
sebum and surface pH using Multi Skin Test Centers MC1000
(Courage & Khazaka, Germany) with Complete Skin Investigation
(CSI) software. The device uses speciﬁc probes for measuring skin
parameters and makes it possible to assess, compare and quanti-
tatively analyse changes of biophysical skin conditions related to
atopic dermatitis during the treatment process. The Corneometer
probe measures electrical capacitance of the skin surface for
evaluating moisture. The Sebumeter probe estimates sebum se-
cretion on skin with a photometric method which is independent
of moisture. The Pigmentation measurement probe works based
on the absorption principle. This probe emits light of a deﬁned
wavelength that is absorbed by the melanin, then the receiver
measures the amount of light reﬂected from the skin. Recorded
values of moisture, sebum and skin pigmentation are expressed as
arbitrary units (AU) on a scale from 0 to 99. In order to measure
the elasticity of the skin by the suction method, the skin is sucked
by a special probe under a negative pressure of 400 mbar for three
seconds and, after stopping the negative pressure, the skin is re-
leased by the probe within the next three seconds. With this
method, the amount of skin resistance to pressure in relation to its
ability to return to its original position is expressed as a percen-
tage, where a higher percentage represents healthier skin. The pH
meter measures skin surface pH using a glass electrode. The ad-
vantage of this method is to minimize the possibility of human
error in estimating skin barrier function and the severity of skin
changes, using non-invasive bioengineering methods (Knor et al.,
2011; Sator et al., 2003).
In this study, the primary outcome variables were measured
using the device mentioned above by a physician at three points of
the anterior forearm and the average was calculated. The patients
were also asked to report pruritus and sleep disturbance due to
itching over the preceding three days depending on the severity of
symptoms from zero to 10 (zero indicates absence and 10 re-
presents the maximum value) to be included as the secondary
outcome variables (The European Task Force on Atopic Dermatitis,
1993). These assessments were carried out in all patients upon
admission (week zero), 15 days after receipt of the drug (week
three) and 15 days after the end of the treatment for follow-up
(week ﬁve).
2.4. Sample size
Based on statistical calculations with the default power (1β)
0.95, type I error (α) 0.05, 20% improvement in drug efﬁcacy
variables (X X1 2¯ − ¯ ) and the group variance (S1 and S2) about 25%,
and with the overall sample size formula
n
S S Z Z
X X
1
2
2
2
1 1
2
1 2
2
2( )( )
( )
=
+ +
¯ − ¯
β− −α
the estimated sample size was 40 subjects. With a 30% possibility
of withdrawal rate, a sample size of 52 patients (26 patients in the
medicine group and 26 patients in the placebo group) was
considered.
2.5. Randomization and blinding
Using the randomization table designed by an independent
statistician, random numbers successively were assigned to the
patients and they were equally randomized into two groups. All
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placebo group. In this study, the evaluating physicians had not
been in contact with the statistician and clinical pharmacist and
were kept blinded to allocation. Patients were also unaware until
the study was completed that they had received the drug or a
placebo.
2.6. Statistical analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS), version 16. Continuous variables were
expressed as mean7SEM.
In the case of each variable, a t-test was conducted in order to
determine whether there is a signiﬁcant difference between the
drug and placebo groups. Repeated measures ANOVA was used for
analysis between and within the groups at weeks zero, three and
ﬁve. The level of signiﬁcance was established at 0.05.3. Results
3.1. Patient enrolment and/or exclusion
A total of 52 patients participated in the study from February to
July 2014, 26 patients were randomized in the placebo group and
26 patients in the treatment group. During the 30-day study, 10WaDSE group 
(n=26)
Enrolm
(n=5
Random
(n=5
2 excluded 
1 poor compliance 
1 use of prohibited drugs 
Completed the 15-day 
treatment (n=24) 
Analysed (n=24)
Completed the 15-day 
follow-up (n=24) 
Fig. 1. Enrolment, randomizatiopatients (two patients in the treatment group and eight patients in
the placebo group) were excluded from the study population for
the following reasons: within the ﬁrst 15 days of study, one in the
treatment group and three in the placebo group were excluded
because of poor compliance and one in the treatment group due to
use of prohibited drugs. During the second half of the study per-
iod, ﬁve patients in the placebo group (one due to disease pro-
gression and four due to being busy) refused to continue with the
follow-up and were excluded.
The number of patients who completed the study and were
analysed was 42 (87%), 24 and 18 patients in the treatment and
placebo groups, respectively. This information is summarised in
the ﬂowchart shown in Fig. 1.
Table 1 shows the baseline characteristics of the groups. There
was no signiﬁcant difference between the treatment and placebo
groups in terms of age, sex, AD family history and duration of
disease. In addition, there was no signiﬁcant difference between
the treatment and placebo groups at baseline in terms of skin
moisture, elasticity, pigmentation, pH and sebum content.
3.2. Efﬁcacy
The efﬁcacy outcomes are shown in Table 2 and Fig. 2. At the
end of the 30-day period of study, in terms of the primary out-
come, the value of skin moisture and elasticity variables in the
group receiving WaDSE was clearly signiﬁcant compared to that ofPlacebo group 
(n=26)
ent 
2) 
ized 
2) 
Completed the 15-day 
treatment (n=23) 
Analysed (n=18)
3 excluded 
Poor compliance 
5 excluded 
1 disease progression 
4 being busy  
Completed the 15-day 
follow-up (n=18) 
n and treatment ﬂowchart.
Table 1
Baseline characteristics of patients.
Variable WaDSE Placebo p-Value
Gender (female)a 20 (83.3) 16 (88.8) 0.621
Age (years)b 28.6272.30 24.3371.50 0.155
Duration of AD (years)b 13.4571.82 12.7772.09 0.760
Positive familial history of ADa 11 (45.8) 8 (44.4) 0.931
Skin moistureb 13.4372.08 19.7272.59 0.063
Skin elasticityb 56.0475.32 61.7375.76 0.476
Skin pigmentationb 22.6671.64 23.1572.42 0.864
Skin surface pHb 5.8070.10 5.7070.11 0.546
Skin sebumb 0.8770.25 1.0370.41 0.725
Pruritusb 5.7070.45 4.7270.39 0.122
Sleep disturbanceb 2.4170.57 1.6170.24 0.255
Abbreviations: WaDSE, whey associated with dodder seed extract; AD, atopic
dermatitis.
a Data presented as number of patients (percentage).
b Data presented as mean7SEM.
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group comparisons, within the group receiving WaDSE, the skin
moisture and elasticity from the baseline values to the end of
treatment signiﬁcantly increased (po0.001). While, there was no
signiﬁcant change in terms of skin pigmentation between the two
groups (p¼0.158), in the WaDSE group skin pigmentation was
reduced quite signiﬁcantly with time (po0.001). There was no
signiﬁcant difference in skin surface pH and sebum between the
two groups (p-Values are 0.757 and 0.443, respectively). Regarding
the itching as a secondary outcome, after 15 days of receiving the
medicine or the placebo a signiﬁcant difference between the two
groups was created (po0.05), which was also signiﬁcant at the
end of thirty days (po0.001). Comparison of sleep disturbance
showed signiﬁcant changes between two groups (po0.05), and at
the end of the study a considerable improvement in subjective
sleep disturbance was demonstrated in the WaDSE group
(po0.001).3.3. Safety Proﬁle
In the WaDSE group, 13 patients (54.1%) reported anorexia, and
four patients (16.6%) reported mild gastrointestinal problems, such
as dyspepsia and a feeling of heaviness in the stomach after ad-
ministration of the drug. It is worth noting that all these side ef-
fects were temporary. Other important side effects were not re-
ported. Abnormality in liver and kidney function tests, blood cell
count, as well as changes in blood pressure and body weight were
not observed.Table 2
Change in variables during the study period.
Variable Week 3
WaDSE Mean7SEM Placebo Mean7SEM p
Skin moisture 20.9772.02 19.4472.44 0
Skin elasticity 70.9774.29 63.4874.95 0
Skin pigmentation 20.7571.63 23.3172.47 0
Skin surface pH 5.6670.10 5.7470.11 0
Skin sebum 1.2070.33 1.0370.40 0
Pruritus 2.7570.41 4.8370.45 0
Sleep disturbance 0.7970.26 1.5070.30 0
Abbreviations: WaDSE, whey associated with dodder seed extract; SEM, standard error
nn po0.001.
n po0.05.4. Discussion
The current study indicated the prescription of whey associated
with dodder seed extract to cause a clear and considerable in-
crease of skin moisture and elasticity, decrease of pigmentation,
reduced itching and improvement of sleep disturbance in patients
with atopic dermatitis. Comparisons of mean7SEM of patients
receiving WaDSE revealed degrees of skin moisture and elasticity
to be enhanced by approximately 100% and 40%, respectively.
An increase in elasticity, decrease in pigmentation, reduced
itching and improvement of sleep disturbance occurring sub-
sequent to reduced itching may be considered as a direct result of
skin moisture enhancement. Notably, it can be said that although
the patients received WaDSE only within the ﬁrst 15 days of the
study, skin moisture and elasticity continued to increase during
the second half of the study (follow-up period). This result high-
lights that the effect of WaDSE is not transient; moreover, the drug
actually contributes to the reconstruction of the skin barrier and is
therefore effective in terms of the skin parameters by accelerating
the trend of skin repair. Additionally, a decrease of skin pigmen-
tation in patients consuming WaDSE proposes the efﬁcacy
of this drug in the improvement of post-inﬂammatory
hyperpigmentation.
Skin barrier malfunctions caused by genetic and environmental
factors, as well as immune system dysregulation is of the main
pathophysiologic aspects of atopic dermatitis (Leung et al., 2004).
Ceramide deﬁciency as the major component of stratum corneum
lipids and the main retaining factor of extracellular space water
leads to epidermal water loss. Consequently, skin dryness occurs,
which involves numerous pores and cracks, and enables the pe-
netration of pathogens, antigens and irritants, subsequently lead-
ing to infection and inﬂammation (Cork et al., 2006).
A wide range of essential and non-essential amino acids, mi-
nerals, lipids and biologically active proteins such as lactoferrin,
beta-lactoglobulin, alpha-lactalbumin, glycomacropeptide and
immunoglobulins exist in whey, giving it a high nutritional value
(Walzem et al., 2002). Due to its rich protein content, whey pro-
vides the possibility for better skin repair and proper skin barrier
function (MacKay and Miller, 2003). On the other hand, lactoferrin
present in whey is involved in bacteriostatic, bacteriocidal and
anti-fungal activities (Farnaud and Evans, 2003; Orsi, 2004), and
indicates that whey consumption in AD patients can reduce sec-
ondary bacterial and fungal infections in skin lesions.
Studies demonstrated that the consumption of whey is asso-
ciated with an increase in serotonin level, leading to an increased
ability for coping with stress (Markus et al., 2002). This in turn can
inﬂuence the promotion of psychological health among AD pa-
tients whose quality of life has been negatively impacted as a re-
sult of the long-term tendency of the disease and its complicationsWeek 5
WaDSE Mean7SEM Placebo Mean7SEM p
.629 29.9171.68 17.6672.20 o0.001nn
.261 79.0172.96 59.3074.99 o0.001nn
.375 19.8171.54 23.8272.47 0.158
.619 5.6270.07 5.6670.09 0.757
.753 1.2270.36 1.0870.41 0.799
.002n 2.0470.32 5.3870.45 o0.001nn
.086 0.6670.20 1.7770.32 0.005n
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serotonin is an immune modulator and plays a role in reducing
itching by suppressing T cells (Kim, 2012).
Studies have shown that whey intake, even in infants with a
positive family history, compared to standard formulas can reduce
the risk of atopic dermatitis in the future (Alexander et al., 2010).
One whey component called milk basic protein (MBP) stimu-
lates the proliferation and differentiation of osteoblasts. Hence, the
authors theorize that the administration of whey in patients with
moderate-to-severe atopic dermatitis that are predisposed to de-
creased bone mineral density, due to the inﬂammatory nature of
the disease and the effects of long term use of corticosteroids, can
beneﬁt by reducing the risk of osteoporosis and osteopenia (Aalto-
Korte and Turpeinen, 1997; Haeck et al., 2009).
Although the use of traditional medicines has been highly re-
garded in the treatment of atopic dermatitis, few studies exist to
assess the efﬁcacy of these drugs within the framework of a
double-blind, placebo-controlled clinical trial (Chen et al., 2015;
Hon et al., 2011; Tan et al., 2013). Whey associated with dodder
seed extract, which is applied in the treatment of chronic and
severe atopic dermatitis in traditional medicine, is in fact a func-
tional food widely used as a nutritional supplement. Various
clinical trials have been conducted that have proven its useful
effects on the treatment of cancer, HIV, hepatitis B, cardiovascular
diseases, osteoporosis and microbial diseases, while no serious
side effects have been reported (Marshall, 2004).
The ﬁeld dodder seed, the decoction of which is used in tra-
ditional medicine in the treatment of atopic dermatitis, possesses
anti-inﬂammatory and anti-proliferative properties due to the
ﬂavonoids quercetin, kaempferol and rutin (Hämäläinen et al.,
2007; Lee et al., 2011). One of the main pathophysiologic aspects of
AD is immune system dysregulation, especially related to the two
main subgroups of CD4þ T cells, i.e., T-helper 1 and T-helper 2
(Leung et al., 2004). Quercetin can have a considerable anti-in-
ﬂammatory role through the inhibition of cytokine production by
T-helper cells (Yu et al., 2008). Quercetin blocks substances in-
volved in allergies and has the ability to act as an inhibitor of mast
cell secretion, which is critically involved in the pathogenesis of
AD (Shaik et al., 2006). Recent studies have shown that heat
processing causes a considerable increase of quercetin within ﬁeld
dodder seeds compared to unprocessed seeds, consequently in-
tensifying its anti-inﬂammatory and anti-proliferative properties
(Lee et al., 2011). In addition, the ﬂavonoids quercetin and
kaempferol show anti-inﬂammatory effects by modulating the
pro-inﬂammatory factors, such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) (García-Mediavilla et al.,
2007). Nitric oxide (NO) derived from inducible NO synthase
(iNOS) is involved in the pathogenesis of allergic rhinitis and ex-
acerbation of atopic dermatitis symptoms like scratching (Orita
et al., 2011). Thus, it is concluded that consuming the aqueous
extract of ﬁeld dodder seeds can be helpful for the improvement of
AD lesions due to decrease of inﬂammation. Its consumption
produces no hepatic or renal complications, but in cases of over-
dose, intestinal colic and diarrhoea may occur (Gruenwald et al.,
2004).5. Conclusions
It can be said that WaDSE is efﬁcient in the treatment of atopic
dermatitis through the functioning of different mechanisms. Fo-
cusing on skin barrier dysfunction and immune system dysregu-
lation, WaDSE can satisfy the main purpose of treatment, which is
reducing the severity and ﬂare-ups of the disease. The results of
this study demonstrate that WaDSE can provide a suitable treat-
ment for moderate-to-severe AD with the lowest incidence ofcomplications and could even be posed as an alternative for sys-
temic and highly morbid treatments. Despite short-term pre-
scription of the mentioned drug in this study, skin moisture and
elasticity underwent considerable enhancement.
Since changes in skin pH and sebum content displayed a long-
term trend, other controlled trials over longer periods of time and
with larger sample sizes should be performed on the parameters
related to the assessment of the drug efﬁcacy. Moreover, im-
plementation of other clinical trials with longer follow-up periods
will be able to evaluate the effects of this drug on the relevant
atopies, such as asthma and allergic rhinitis.Acknowledgements
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